OBIO
Orchestra BioMed Holdings Inc

513
Loading...
Loading...
News
all
press releases
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q2 Loss, Beats Revenue Estimates
Orchestra BioMed Holdings, Inc. (OBIO) delivered earnings and revenue surprises of +1.96% and +16.11%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
More News
News Placeholder
CRISPR Therapeutics AG (CRSP) Reports Q2 Loss, Lags Revenue Estimates
CRISPR Therapeutics (CRSP) delivered earnings and revenue surprises of +12.24% and -86.45%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q1 Loss, Tops Revenue Estimates
Zacks·4mo ago
News Placeholder
Ultragenyx (RARE) Reports Q1 Loss, Misses Revenue Estimates
chainwire·4mo ago
News Placeholder
Orchestra BioMed Holdings Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag
Orchestra BioMed Holdings ( NASDAQ:OBIO ) Full Year 2023 Results Key Financial Results Net loss: US$49.1m (loss widened...
Simply Wall St·1y ago
News Placeholder
Orchestra BioMed Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update
Initiated enrollment of the BACKBEAT global pivotal study evaluating AVIM therapy (also known as BackBeat Cardiac Neuromodulation Therapy) in hypertensive pacemaker patients in collaboration with...
Globe Newswire·1y ago
News Placeholder
Orchestra BioMed Announces Appointment of Medical Device Industry Expert David Pacitti to Board of Directors
David Pacitti is currently the President of Siemens Medical Solutions USA, Inc. and Head of the Americas, Siemens Healthineers; formerly Division Vice President of U.S. Commercial Operations, Sales...
Globe Newswire·1y ago
News Placeholder
Orchestra BioMed Demonstrates Strength of Cardiovascular Pipeline with Virtue SAB and AVIM Therapy Presentations at CRT 2024 Annual Meeting
New pharmacokinetic data demonstrate Virtue SAB enables extended release of sirolimus above required tissue concentrations in target arterial sites without polymer degradation or detectable...
Globe Newswire·2y ago
News Placeholder
Orchestra BioMed to Participate in Upcoming Investor Conferences
NEW HOPE, Pa., March 07, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, Orchestra BioMed or the Company ), a biomedical company accelerating high-impact technologies to...
Globe Newswire·2y ago
News Placeholder
Orchestra BioMed Announces Presentation of Results from Clinical Study Demonstrating Favorable Hemodynamic Effects of AVIM Therapy In Hypertensive Pacemaker Patients
Clinical study evaluated impact of AVIM therapy as compared to standard pacing using invasive pressure-volume loop analysis in 16 hypertensive pacemaker-indicated patients Results demonstrate...
Globe Newswire·2y ago

Latest OBIO News

View

Advertisement. Remove ads.

Advertisement. Remove ads.